ABCELLERA BIOLOGICS
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treat… Read more
ABCELLERA BIOLOGICS (8QQ) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ABCELLERA BIOLOGICS (8QQ) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ABCELLERA BIOLOGICS - Net Assets Trend (None–None)
This chart illustrates how ABCELLERA BIOLOGICS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ABCELLERA BIOLOGICS (None–None)
The table below shows the annual net assets of ABCELLERA BIOLOGICS from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ABCELLERA BIOLOGICS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ABCELLERA BIOLOGICS Competitors by Market Cap
The table below lists competitors of ABCELLERA BIOLOGICS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Biotest Aktiengesellschaft
PINK:BIESF
|
$640.35 Million |
|
Collins Foods Limited
PINK:CLLFF
|
$640.38 Million |
|
Edifier Technology Co Ltd
SHE:002351
|
$640.66 Million |
|
Shanghai SK Automation Technology Co. Ltd. A
SHG:688155
|
$641.08 Million |
|
Cyfrowy Polsat S.A
OTCGREY:CYFWF
|
$640.25 Million |
|
Weis Markets Inc
NYSE:WMK
|
$639.66 Million |
|
Jiangsu Provincial Agricultural Reclamation and Development Co Ltd
SHG:601952
|
$639.55 Million |
|
Wuhan Zhongyuan Huadian Sci Tech
SHE:300018
|
$639.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ABCELLERA BIOLOGICS's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ABCELLERA BIOLOGICS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ABCELLERA BIOLOGICS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ABCELLERA BIOLOGICS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ABCELLERA BIOLOGICS (8QQ) | €- | N/A | N/A | $640.32 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |